Updated:
Dyne Therapeutics
Dyne Therapeutics, led by CEO John Cox, is advancing targeted muscle-disease therapies through its FORCE and ACHIEVE platforms.
Dyne Therapeutics
Dyne Therapeutics was formed to transform the treatment of genetically driven muscle diseases. It shares a Cambridge headquarters with the densest biotech cluster on the East Coast. The firm's public listing on Nasdaq under ticker DYN subjects it to quarterly disclosure, giving external observers an unusual window into its balance sheet and pipeline progress. Its founding team and early backers have not been widely chronicled, but the company's SEC filings confirm it emerged from Atlas Venture's incubator with a FORCE platform targeting myotonic dystrophy type 1. John Cox, who joined as CEO in 2020 after running Editas Medicine's commercial strategy, directs a pipeline built around two conjugate platforms. FORCE aims at muscle tissue, starting with DYNE-101 for myotonic dystrophy type 1; ACHIEVE targets the central nervous system, led by DYNE-102 for facioscapulohumeral muscular dystrophy. Both assets are in Phase 1/2 trials. In addition, a preclinical Pompe disease candidate uses the ACHIEVE backbone. The firm's therapeutic focus spans the US and EU markets. Dyne also cuts a small-molecule program, DYNE-301, for Duchenne muscular dystrophy, which remains in late preclinical development. The company reported 231 employees at year-end 2023, with operations concentrated in the US. A key operational event arrived in January 2025, when Dyne dosed the first patient in the registrational DELIVER trial for DYNE-101, aiming to confirm accelerated approval endpoints in myotonic dystrophy type 1. The company has not disclosed adjacent philanthropic vehicles or club memberships. Dyne's structural differentiator lies in its execution posture. It is not yet revenue-generating, carrying late-stage clinical risk on two separate platforms with no Big Pharma co-development partner. The $629 million cash runway reported for 2025 buys an independent path to pivotal readouts. That self-funded autonomy—rare in a mid-cap biotech—defines its investment proposition for allocators considering the public equity.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cambridge
Corporate office
Cambridge, MA, United States
Principals
John Cox
President and Chief Executive Officer
Wildon Farwell
Chief Medical Officer
Susanna High
Chief Operating Officer
Sector focus
Frequently asked questions
What therapeutic platforms does Dyne Therapeutics operate?
The firm runs two conjugate platforms: FORCE, which targets muscle tissue, and ACHIEVE, which targets the central nervous system. FORCE's lead candidate is DYNE-101 for myotonic dystrophy type 1. ACHIEVE's lead is DYNE-102 for facioscapulohumeral muscular dystrophy. Both platforms use antibody-fragment conjugates to deliver oligonucleotide payloads.
How does Dyne fund its clinical pipeline without product revenue?
Dyne is a publicly traded biotech that funds operations through equity offerings. Its 2025 annual report disclosed $629 million in cash and equivalents, which management expects to fund operations through key registrational readouts. The firm has no revenue from marketed products and reports a net loss each quarter consistent with a clinical-stage drug developer.
Which muscle diseases does Dyne target?
Confirmed programs include myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The Duchenne candidate DYNE-301 is a small molecule; the rest use the conjugate platforms. Clinical-stage assets are DYNE-101 and DYNE-102.
Who leads the company's clinical and regulatory strategy?
Wildon Farwell, MD, serves as Chief Medical Officer, overseeing clinical development and regulatory interactions. He joined Dyne in 2020 after holding development leadership roles at Biogen and Alnylam. The board includes experienced drug developers from Vertex and Alexion.
Is Dyne Therapeutics a family office?
No. Dyne Therapeutics is a clinical-stage public biotechnology company, structured as a Delaware corporation listed on Nasdaq. It is not a family office, and its capital comes from institutional shareholders and public market investors, not a single family's wealth. The firm was incorrectly categorized as a family office in a prior database mapping.
What is the registrational pathway for DYNE-101?
Dyne initiated the DELIVER trial in January 2025, a registrational study for DYNE-101 in myotonic dystrophy type 1. The trial is designed to confirm endpoints that could support accelerated approval. The company has not projected a biologics license application filing date.
Does Dyne retain full rights to its pipeline?
Yes. As of early 2026, public disclosures show no licensing, co-development, or profit-sharing agreements with larger pharmaceutical partners. Dyne holds worldwide commercial rights to all disclosed programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: